FacebookTwitterRedditEmail

Suicide and Cymbalta

Ask about published reports of 470 completed suicides of people on antidepressants since Prozac debuted in 1988 and the drug industry will say that’s depression for you. Without our drugs, it would be worse.

But how does Eli Lilly and Co. explain the mounting suicides of people given Cymbalta (duloxetine) for urinary incontinence or peripheral neuropathy?

The planned debut of Cymbalta, now Lilly’s number two drug, was even delayed by the suicide of a non-depressed person in 2004.

Traci Johnson, a healthy 19-year-old college student volunteer enrolled in a Cymbalta trial hung herself by a scarf from a shower rod in Lilly’s Indianapolis, IN laboratory while withdrawing from the drug.

Johnson showed no outward signs of depression and Lilly said she had been screened for mental problems, but staff conducting a concurrent Cymbalta trial made comments about her “mental history” to at least four participants–perhaps to keep them from dropping out of the trials as a fifth of volunteers did after the suicide.

After Johnson’s death, Lilly was ordered to stop accepting new volunteers for the study and to have continuing participants evaluated by an independent psychiatrist and sign new consent forms. But in another Cymbalta trial of 4,124 depressed patients just weeks later, four more participants took their lives according to a Lilly clinical psychiatrist, Dr. John R. Hayes.

Meanwhile reports from abroad where duloxetine was already in use as a stress urinary incontinence treatment called Yentreve were just as grave.

Twice the expected number of suicide attempts among middle aged women were seen with the drug– 400 per 100,000 person-years versus a baseline of 160 per 100,000 person-years–said the FDA on its Web site in June, 2005, leading Lilly to precipitously withdraw its application to sell Yentreve in the US.

Safety data for Cymbalta and Yentreve obtained by reporter Jeanne Lenzer under a Freedom of Information request for a Independent on Sunday article disclosed 41 deaths and 13 suicides which did not include Johnson’s or the four cited by Hayes, says Lenzer.

In fact in an article titled,” Duloxetine: new drug. For stress urinary incontinence: too much risk, too little benefit,” in the December 2005 issue of French medical journal Prescire International, the authors conclude that the drug should not even be in use.

More than 40 different types of adverse effects have been reported, including suicide attempts and potentially severe hepatic disorders. (7) Duloxetine is metabolised by the cytochrome P450 isoenzymes CYP 1A2 and CYP 2D6, creating a risk of interactions with other drugs that follow these metabolic pathways. (8) In practice, purely symptomatic treatments that have no documented efficacy but many adverse effects should not be used, especially when there is an alternative treatment with a positive risk-benefit balance.

The FDA approved Cymbalta for depression and diabetic peripheral neuropathy in 2004 and generalized anxiety disorder in 2007. But last fall it ordered Lilly to stop downplaying liver toxicity in its promotional materials.

And an article in the January 2007 issue of Diabetes Care found Cymbalta actually raises fasting blood glucose which can worsen the diabetic peripheral neuropathy it is supposed to treat. (see: depression; causes and effects)

Cymbalta has other side effects too, say users in email messages to a reporter.

In Jim Ellsworth, 52 of Houlton, Maine it caused a “hypertensive crisis” that did not fully subside until a month after quitting the drug he says.

It caused “involuntary twitching and jerking motions” that persist three years after being off Cymbalta for fibromyalgia says Lonna.

And for Amy, who had no history of depression but was “given Cymbalta for Attention Deficit Disorder, (which I haven’t been able to find anywhere that it is even approved for that)” it caused a withdrawal in which she “went on rampages and cried over everything and felt so sick and awful that I didn’t think I wanted to live anymore.”

But worst are the out of character, almost matter of fact suicides like a man described by his family as, “NOT depressed, he was a fun-loving guy with all sorts of plans in place for the future,” who was prescribed Cymbalta for foot pain.

He “had a normal day at work, drove home, said he was going to grab a sandwich to his wife, and went and shot himself.”

With its number one drug, Zyprexa on the ropes–Alaska and Louisiana sued Lilly for the Medicaid costs of treating Zyprexa-caused diabetes and CEO John C Lechleiter was caught promoting it off label by the New York Times–Lilly is marketing Cymbalta like its pipeline depends on it.

It used 500 sales reps from slick contract sales organization Quintiles International to launch Cymbalta as well an unspecified number of its own reps and hopes to get approval for fibromyalgia while doctors are still writing the drug.

But bad press for Cymbalta might start sooner than Lilly expects–in a wrongful death suit of Carol Gotbaum who strangled herself with handcuffs while in police custody at the Sky Harbor International Airport in Phoenix, AZ in September.

Press reports say the 45-year-old daughter-in-law of a New York City elected official and prominent labor leader was under the influence of Cymbalta.

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

 

 

 

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

March 25, 2019
Dave Lindorff
The TSA’s Role as Journalist Harasser and Media ‘Watchdog’
Jonathan Cook
Three Lessons for the Left from the Mueller Inquiry
Tanya Golash-Boza – Michael Golash
Epifanio Camacho: a Militant Farmworker Brushed Out of History
Robert Fisk
Don’t Believe the Hype: Here’s Why ISIS Hasn’t Been Defeated
Jack Rasmus
The Capitulation of Jerome Powell and the Fed
Lawrence Davidson
Israel’s Moves to the Right
John Feffer
After Trump
James Ridgeway
Good Agent, Bad Agent: Robert Mueller and 9/11
Dean Baker
The Importance of Kicking Up: Changing Market Structures So the Rich Don’t Get All the Money
Lawrence Wittner
What Democratic Socialism Is and Is Not
Thomas Knapp
Suppressing Discussion Doesn’t Solve the Problem. It is the Problem.
Stephen Cooper
“I’m a Nine-Star General Now”: an Interview with Black Uhuru’s Duckie Simpson
Andrew Moss
Immigration and the Democratic Hopefuls
Weekend Edition
March 22, 2019
Friday - Sunday
Henry Giroux
The Ghost of Fascism in the Post-Truth Era
Gabriel Rockhill
Spectacular Violence as a Weapon of War Against the Yellow Vests
H. Bruce Franklin
Trump vs. McCain: an American Horror Story
Paul Street
A Pox on the Houses of Trump and McCain, Huxleyan Media, and the Myth of “The Vietnam War”
Andrew Levine
Why Not Impeach?
Bruce E. Levine
Right-Wing Psychiatry, Love-Me Liberals and the Anti-Authoritarian Left
Jeffrey St. Clair
Roaming Charges: Darn That (American) Dream
Charles Pierson
Rick Perry, the Saudis and a Dangerous Nuclear Deal
Moshe Adler
American Workers Should Want to Transfer Technology to China
David Rosen
Trafficking or Commercial Sex? What Recent Exposés Reveal
Nick Pemberton
The Real Parallels Between Donald Trump and George Orwell
Binoy Kampmark
Reading Manifestos: Restricting Brenton Tarrant’s The Great Replacement
Brian Cloughley
NATO’s Expensive Anniversaries
Ron Jacobs
Donald Cox: Tale of a Panther
Joseph Grosso
New York’s Hudson Yards: The Revanchist City Lives On
REZA FIYOUZAT
Is It Really So Shocking?
Bob Lord
There’s Plenty of Wealth to Go Around, But It Doesn’t
John W. Whitehead
The Growing Epidemic of Cops Shooting Family Dogs
Jeff Cohen
Let’s Not Restore or Mythologize Obama 
Christy Rodgers
Achieving Escape Velocity
Monika Zgustova
The Masculinity of the Future
Jessicah Pierre
The Real College Admissions Scandal
Peter Mayo
US Higher Education Influence Takes a Different Turn
Martha Rosenberg
New Study Confirms That Eggs are a Stroke in a Shell
Ted Rall
The Greatest Projects I Never Mad
George Wuerthner
Saving the Big Wild: Why Aren’t More Conservationists Supporting NREPA?
Norman Solomon
Reinventing Beto: How a GOP Accessory Became a Top Democratic Contender for President
Ralph Nader
Greedy Boeing’s Avoidable Design and Software Time Bombs
Tracey L. Rogers
White Supremacy is a Global Threat
Nyla Ali Khan
Intersectionalities of Gender and Politics in Indian-Administered Kashmir
Karen J. Greenberg
Citizenship in the Age of Trump: Death by a Thousand Cuts
Jill Richardson
Getting It Right on What Stuff Costs
FacebookTwitterRedditEmail